PubMed Health⌕ Search

Biomedical subjects

T Akagi

Publications and source records attributed to T Akagi.

At least 307 records · Page 17Linked to original sources
PubMed1987

[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].

Eleven patients with advanced adenocarcinoma of the prostate were treated with a cyclic alternating chemotherapy (VIP-DMF therapy), consisting of a three-drug combination of vincristine, ifosfamide, and peplomycin; and a three-drug combination of adriamycin, mitomycin C and 5-fluorouracil. Each cycle was repeated every 3 or 4 weeks. Of these patients, 9 were refractory to prior hormonal therapy and 8 (89%) achieved an objective response (3 partial, 6 stable) using the criteria of the U.S. National Prostatic Cancer Project. In the patients showing objective response, the duration was from 3 to 18 months with a median duration of 6 months. The survival periods from the initiation of chemotherapy in effective cases ranged from 6 to 20+ months with a median duration of 11 months. The major toxicity was myelosuppression, although no patients suffered life-threatening toxicity. We consider that VIP-DMF therapy is a useful regimen for the treatment of advanced prostatic cancer.

Adenocarcinoma↗
PubMed1987

[Intravesical chemotherapy with interferon in superficial bladder tumors].

Interferon (IFN) was used in the treatment of superficial bladder tumors. Interferon (IFN-beta, IFN-gamma) was instilled into the bladder at dosages ranging from 16 billion to 36 billion U IFN per 30 ml physiological saline. The IFN was instilled into the bladder once a day or twice a day for 10 to 20 days. In this trial, ten patients with superficial bladder tumors were treated at Okayama City Hospital, and of these, 1 CR, 3 PR, 2 MR and 4 NC were obtained. There were no signs of either irritable bladder or general side effects. IFN (especially IFN-beta) is considered a useful drug for superficial bladder tumors in intravesical chemotherapy.

Administration, Intravesical↗
PubMed1987

[A new anti-cancer agent, bestrabucil (KM 2210): I. Concentration in the serum and tissue in urogenital tumors].

Serum and tissue concentrations of bestrabucil (KM 2210), a combined agent of 17-estradiol and Chlorambucil, were examined in patients with urogenital cancers including those of the kidney, bladder, prostate and testis. We administered orally 100mg (50 mg X 2/day of bestrabucil for 3 days), and determined its plasma levels and metabolites. A maximum drug concentration, i.e., 9.25 ng/ml, was noted 3 hours after administration; a constant plasma level of 5 ng/ml was maintained and the concentration of free chlorambucil was low. After single or consecutive oral administration of bestrabucil (100-300 mg), tumor specimens contained significantly large amounts of bestrabucil in comparison with adjacent normal tissue. Selective accumulation of the active component in tumor tissue suggests the clinical usefulness of bestrabucil.

Administration, Oral↗
PubMed1986

Transformation of hamster spleen lymphocytes by human T-cell leukemia virus type I.

Co-cultivation of spleen cells of Syrian golden hamsters with lethally irradiated MT-2 cells harboring human T-cell leukemia virus type I (HTLV-I) resulted in the establishment of lymphoid cell lines, HCT-1 and HCT-2, which exhibited the normal karyotype of golden hamsters. Cells of both the HCT-1 and HCT-2 lines lacked surface immunoglobulins and reacted with a monoclonal antibody (MAb) specific for hamster T cells. Some were positive for OKIa1. None of them expressed HTLV structural antigens (p19 and p24) or virus particles, but they contained HTLV-I proviral DNA monoclonally. By immunochemical analysis of the labelled cell antigens, sera from adult T-cell leukemia (ATL) patients reacted with the two polypeptides, p37 and p40, which may not be viral structural proteins and still remain to be characterized. HCT-1 and HCT-2 cells were transplantable into newborn hamsters, pre-treated with anti-hamster thymocyte serum and non-treated, respectively, producing diffuse malignant lymphoma. These findings indicated that HTLV-I not only immortalized but also transformed hamster T cells non-productively.

Animals↗
PubMed1986

Intravesical chemotherapy with 4'-epi-Adriamycin in patients with superficial bladder tumors.

We evaluated the effects of 4'-epi-Adriamycin (EPI), a derivative of Adriamycin (ADR), in intravesical instillation chemotherapy. The patients received two courses of three daily instillations of 50-80 mg EPI dissolved in 30 ml physiological saline on 3 consecutive days, with an interval of 4 days between courses. Full evaluation was possible in 33 of 35 patients with superficial bladder tumors treated with EPI. Complete response was observed in 4 cases and partial response in 14 cases, giving a response rate of 55%. Side effects such as pollakiuria and pain on micturition occurred in 9 cases. EPI appears to be an effective agent for intravesical instillation chemotherapy in patients with superficial bladder tumors.

Adult↗
PubMed1986

Electron microscopic and immunohistochemical observations of differentiation of human myeloid leukemia line, PL-21.

A new human myeloid leukemia cell line, PL-21, consisting of promyelocytes, was microscopically and immunohistochemically studied for their maturation induced by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and retinoic acid (RA). More than 80% of PL-21 cells cultured for 4 days with 10 ng/ml of TPA became macrophage-like cells with functional and histochemical properties consistent with monocytes/macrophages. The cells adhered to the plastic flask, developed phagocytic activity and macrophage-specific intracytoplasmic alpha subunit of S-100 protein, and had reduced myeloid-specific cytochemical markers. In contrast, RA-treated PL-21 cells displayed mature neutrophil-like morphology after 7 days of exposure. Most of the cells had reduced nitro blue tetrazolium and acquired phagocytic activity with persistence of myeloid-specific cytochemical markers such as peroxidase, naphthol-AS-D chloroacetate esterase, and Sudan black B. These results indicate that the PL-21 cell line ca be induced to mature into two directions of macrophages and neutrophils by chemical inducers, and will provide a useful tool for studying the differentiation of leukemic cells and searching for other differentiation inducers.

Cell Differentiation↗
PubMed1986

Primary rhabdomyosarcoma combined with chronic paragonimiasis in the cerebrum: a necropsy case and review of the literature.

A necropsy case of a primary rhabdomyosarcoma with chronic paragonimiasis in the cerebrum of a 68-year-old man is reported. The clinical data showed a right hemiplegia and dysarthria which became lethal in 6 months even though operation and radiation therapy were performed. Computed tomography revealed a large low-density area associated with the peripheral enhancement in the left basal ganglia, and multiple conglomerated calcified masses in the left temporal and occipital lobes. Biopsied and necropsied materials of the tumor in the basal ganglia was reddish brown in color and histologically was composed of purely mesenchymal derivatives with both embryonal and mature striated muscle cells but neither neuronal nor glial elements. Some of the tumor cells with extending slender cytoplasms showed obvious cross striations at the light and electron microscope levels and immunohistochemical reactivity for myoglobin. All tumor cells were also positive for vimentin, but not for glial fibrillary acidic protein. The clinical and necropsy findings revealed no primary lesion anywhere but in the brain. In addition, numerous dead oval eggs of Paragonimus westermani were found in many cystoid lesions encapsulated by thick connective tissues with calcification and/or ossification. Clinicopathological features of 24 cases of primary rhabdomyosarcoma of the central nervous system reported in the literature are reviewed briefly. The histogenesis of this tumor are discussed together with comments on cerebral paragonimiasis.

Aged↗
PubMed1986

[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology].

Fundamental and clinical studies of a new carbapenem antibiotic, imipenem/cilastatin sodium (MK-0787/MK-0791), were carried out to evaluate the drug in treating infections of the female genital organs. The following results were obtained: In 4 patients undergoing hysterectomy, the penetration of MK-0787 and MK-0791 into female genital organ tissues was studied following a 30-minute intravenous drip infusion of MK-0787/MK-0791 500 mg/500 mg. Plasma levels of MK-0787 and MK-0791 in cubital venous blood following the drip infusion peaked at 0 minute with values of 51.2 micrograms/ml and 61.9 micrograms/ml, respectively, then decreased to 1.9 micrograms/ml and 0.7 microgram/ml, respectively, at 201 minutes. MK-0787 penetrated readily to female genital organ tissues and levels of the drug exceeded 0.5 approximately 1.9 micrograms/g in various organ tissues at 201 minutes following an intravenous drip infusion of 500 mg/500 mg of MK-0787/MK-0791. Clinically, MK-0787/MK-0791 was used for the treatment of obstetrical and gynecological infections at a dosage of 500 mg/500 mg twice daily by intravenous drip infusion. Clinical effects of MK-0787/MK-0791 were analyzed in 22 patients, including 9 patients with intrauterine infections, 7 with intrapelvic infections, 5 with adnexitis, and 1 with an external genital infection. Excellent responses were seen in 5 patients (22.7%), good responses in 15 (68.2%), and poor responses in 2 (9.1%). The efficacy ratio was 90.9%. After the treatment, 15 out of 18 isolates were eradicated for an 83.3% eradication rate. All strains of S. epidermidis (2 strains), Eubacterium lentum (1 strain), Peptococcus sp. (1 strain), beta-Streptococcus (1 strain), Gram-positive rods (2 strains), Enterobacter cloacae (1 strain), Bacteroides bivius (1 strain), Pseudomonas sp. (1 strain), Pseudomonas cepacia (1 strain) and Gram-negative rods (1 strain) were eradicated by the MK-0787/MK-0791 treatment. The safety of the drug was analyzed in 22 patients, effects occurred in 3 (13.6%). Among those 3 patients, diarrhea occurred in 1 patient, rash in another and nausea and vomiting in yet another. One patient had an increased BUN after the MK-0787/MK-0791 treatment. In the other 21 patients, no abnormalities in creatinine, GOT, GPT, or T. Bil. values were observed. It may be concluded that MK-0787/MK-0791 is useful for the treatment of obstetrical and gynecological infections.

Adolescent↗
PubMed1986

[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology].

Fundamental and clinical studies on imipenem/cilastatin sodium (MK-0787/MK-0791) were carried out and the results obtained were summarized below. The transfer of MK-0787/MK-0791 into female genital organ tissues was found to be satisfactory. The transfer of MK-0787/MK-0791 into umbilical arterial blood, umbilical venous blood and amniotic fluid was relatively good. A dose of 1,000 mg/1,000 mg per day of MK-0787/MK-0791 was given to each of 6 gynecology patients for 5-22 days and satisfactory clinical effect was obtained in 5 patients out of 6 patients. No notable side effects or abnormal laboratory findings were observed except for a moderate in elevation in S-GOT/S-GPT in 1 case.

Adult↗
PubMed1986

[Cystic cerebral tuberculoma--a case report].

A case of cystic cerebral tuberculoma is presented. A 63-year-old man was admitted initially to a sanatorium in May, 1983, for the treatment of pulmonary tuberculosis. He developed headache and vomiting, and suddenly had a right hemiconvulsion on September 27, 1983. Gradually he developed right hemiparesis and motor aphasia. CT scan revealed a well defined, ring-like enhanced mass with multiloculated cysts in the left fronto-parietal lobe. So, he was transferred to our hospital on February 3, 1984. Neurological examination revealed that he had motor aphasia and right hemiparesis. Left carotid angiogram showed light tumor stain in the left fronto-parietal lobe, and 99mTc brain scan detected increased uptake in this area. A left fronto-parieto-temporal craniotomy was performed and a subcortical mass was excised en bloc. The mass had multiloculated cysts containing xanthochromic fluid. Histologically, the mass was cystic cerebral tuberculoma. Cystic cerebral tuberculomas have rarely been reported even before the introduction of antituberculous chemotherapy. The pathogenesis of the cysts in this particular case was considered that the caseous material would have undergone liquefaction by enzymes liberated from degenerated and fragmented inflammatory cells.

Brain Diseases↗